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uclear factor 
 
 
 
B (NF-
 
 
 
B) mediates homeostatic
growth inhibition in the epidermis, and a loss of
NF-
 
 
 
B function promotes proliferation and onco-
genesis. To identify mechanisms responsible for these ef-
fects, we impaired NF-
 
 
 
B action in the epidermis by three
different genetic approaches, including conditional NF-
 
 
 
B
blockade. In each case, epidermal hyperplasia was ac-
companied by an increase in both protein levels and tissue
N
 
distribution of the G1 cell cycle kinase, CDK4. CDK4 up-
regulation required intact TNFR1 and c-Jun NH
 
2
 
-terminal
kinase (JNK) function. 
 
Cdk4
 
 gene deletion concomitant
with conditional NF-
 
 
 
B blockade demonstrated that CDK4
is required for growth deregulation. Therefore, epidermal
homeostasis depends on antagonist regulation of CDK4
expression by NF-
 
 
 
B and TNFR1/JNK.
 
Introduction
 
Nuclear factor 
 
 
 
B (NF-
 
 
 
B)/Rel transcription factors exert im-
portant effects in diverse tissues, including epithelia. NF-
 
 
 
B
subunits are inhibited by inhibitor of 
 
 
 
B (I
 
 
 
B) proteins and are
activated by an upstream cascade involving I
 
 
 
B kinases, which
is controlled by a number of cell surface receptors, such as
TNFR1 (Baldwin, 2001; Dixit and Mak, 2002). In skin, one
role for NF-
 
 
 
B appears to be in the inhibition of epithelial
growth. Epidermis lacking the RelA NF-
 
 
 
B subunit displays
hyperproliferation that is epithelial cell autonomous (Zhang et
al., 2004). RelA inhibits epidermal growth by opposing the
action of another group of TNFR1 effectors, namely the c-jun
NH
 
2
 
-terminal kinase (JNK) cascade (Zhang et al., 2004). NF-
 
 
 
B
epidermal effects are not confined to physiologic growth re-
straint, but have also been implicated recently in epidermal
squamous cell carcinoma (SCC), which is the second most
common cancer in the United States. A majority of human
SCCs display evidence of NF-
 
 
 
B hypofunction, and experi-
mentally induced NF-
 
 
 
B blockade with I
 
 
 
B
 
 
 
 promotes SCC in
both murine and human epidermal tissue (van Hogerlinden et
al., 1999; Dajee et al., 2003; Lind et al., 2004). Therefore, NF-
 
 
 
B
affects epithelial homeostasis as well as carcinogenesis, al-
though the NF-
 
 
 
B targets altering cellular growth in these
settings are unknown.
The critical transition through the G1 phase of the cell
cycle into DNA replication is regulated by CDKs, including
CDK4/6 and their D-type cyclin partners, which act in concert
to remove the mid-G1 Rb block (Murray, 2004). Although
redundancy in CDK–cyclin–mediated G1 progression is clear
(for review see Su and Stumpff, 2004), the functional impor-
tance of G1 CDKs and cyclins is supported by the overlapping
defects resulting from their ablation as well as by their frequent
amplification in human cancers (Cheung et al., 2001; Yasmeen
et al., 2003; for review see Su and Stumpff, 2004). Additionally,
in human epidermal cells, CDK4 down-regulation has been
identified as a safeguard against neoplastic transformation by
oncogenic Ras (Lazarov et al., 2002). In this context, CDK4
protein degradation is triggered by Ras in a process that can be
inhibited by I
 
 
 
B
 
 
 
 (Dajee et al., 2003), suggesting that NF-
 
 
 
B
opposes epidermal tumorigenesis by altering levels of a core
cell cycle regulator. In agreement with this, NF-
 
 
 
B caused
selective CDK4 down-regulation, which led to G1 arrest (Dajee
et al., 2003; Hinata et al., 2003). However, these experiments
relied on overexpression of active NF-
 
 
 
B subunits, and it is un-
certain whether these findings point to a physiologic role for
CDK4 regulation by NF-
 
 
 
B in epidermal growth control.
Here, we demonstrate that interfering with NF-
 
 
 
B
function in epidermis by multiple distinct genetic approaches
increases  expression and tissue distribution of CDK4. This
CDK4 up-regulation is dependent on both TNFR1 and JNK
cascade function, and is consistent with a model in which
TNFR1 originates antagonistic effects on the core cell cycle
machinery through opposing actions by two of its major down-
stream effectors, NF-
 
 
 
B and JNK. 
 
Cdk4
 
 ablation abolished
epidermal growth impacts of conditional NF-
 
 
 
B blockade,
confirming the functional importance of CDK4 in this setting.
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B, inhibitor of 
 
 
 
B; JNK, c-Jun NH
 
2
 
-
terminal kinase; NF-
 
 
 
B, nuclear factor 
 
 
 
B. 
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Antagonist regulation of CDK4 expression by NF-
 
 
 
B and
TNFR1/JNK therefore mediates homeostatic growth control
in epidermis.
 
Results and discussion
 
To study the basis for the growth deregulation that occurs with
NF-
 
 
 
B hypofunction in the nontransformed epidermis, we ex-
amined the levels of cell cycle regulators. We focused initially
on CDK4 because of prior findings in neoplasia overexpression
studies (Dajee et al., 2003). To define effects on CDK4 in the
context of NF-
 
 
 
B subunit loss of function by genetic deletion,
we began with RelA-deficient epidermis. This tissue, generated
by an embryo-grafting approach to immunodeficient mice that
circumvents the mid-gestational embryonic lethality of 
 
RelA
 
knockout mice (Zhang et al., 2004), displayed a markedly more
widespread distribution of CDK4 protein; in contrast, distribu-
tion of another G1 CDK, CDK2, was unaltered (Fig. 1 a). Al-
though normally confined to the proliferative basal layer of ep-
ithelium that is adherent to the underlying basement membrane
zone (BMZ), CDK4 protein was found many cell layers above
the BMZ in RelA-deficient epidermis, which is consistent with
the recently demonstrated expansion of the proliferative cell
compartment that occurs in this context (Zhang et al., 2004).
Quantitatively, CDK4 protein levels were more than fourfold
above the normal level seen in epidermal extracts from RelA-
null tissue (Fig. 1 b). Therefore, NF-
 
 
 
B RelA deficiency leads
to CDK4 up-regulation in nonneoplastic epidermis, indicating
that RelA is required to maintain physiologic CDK4 expression
levels in this setting.
TNFR1 activates NF-
 
 
 
B as well as other effector path-
ways, including the JNK kinase cascade, which has emerged as
a major oppositional force to NF-
 
 
 
B action in a variety of cell
types (De Smaele et al., 2001; Tang et al., 2001; Reuther-
Madrid et al., 2002). In light of recent findings indicating
that NF-
 
 
 
B restrains epidermal proliferation by antagonizing
TNFR1-JNK action (Zhang et al., 2004), we wished to deter-
mine if the CDK4 up-regulation that occurs with NF-
 
 
 
B im-
pairment requires intact TNFR1 and JNK function. To examine
TNFR1, 
 
Tnfr1
 
 
 
/
 
 
 
RelA
 
 
 
/
 
 
 
 double knockout mice were gener-
ated; these mice are viable through the postnatal period (Al-
camo et al., 2001). Epidermal extracts demonstrated no in-
crease in CDK4 levels with RelA deficiency on a TNFR1-null
background (Fig. 2 a), confirming that TNFR1 is required for
the CDK4 up-regulation that occurs with NF-
 
 
 
B loss of func-
tion. TNF
 
 
 
, the major TNFR1 ligand, down-regulated CDK4
protein levels in primary human epidermal cells, indicating that
CDK4 represents a downstream target of TNF action (Fig. 2 b).
CDK4 down-regulation by TNF
 
 
 
 was blocked by expression
of an NF-
 
 
 
B inhibitory I
 
 
 
B
 
 
 
 super-repressor mutant (Van
Antwerp et al., 1996) as well as by active MKK7 (Fig. 2 b). Al-
though neither I
 
 
 
B
 
 
 
 nor MKK7 altered levels of TNFR1 pro-
tein (Fig. 2 c), antibodies to TNFR1 blocked the CDK4 in-
creases seen in epidermal cells expressing I
 
 
 
B
 
 
 
 (Fig. 2 d). JNK
cascade inhibition, via both genetic and pharmacologic means,
also blocked I
 
 
 
B
 
 
 
-driven CDK4 up-regulation in human epi-
dermal cells in vitro (Fig. 2 e). Consistent with prior studies
(Dajee et al., 2003) using overexpression of NF-
 
 
 
B subunits,
altered NF-
 
 
 
B function failed to change CDK4 mRNA levels
significantly (Fig. 2 f), indicating that CDK4 regulation by NF-
 
 
 
B occurs at the posttranscriptional level. Expression of I
 
 
 
B
 
 
 
in genetically engineered human epidermal tissue regenerated
on immunodeficient mice recapitulated the expansion of CDK4
expression seen in RelA null tissue; this expansion was largely
reversed by either coexpression of dominant-negative JNK or
topical application of a JNK inhibitor (Fig. 2 g). Epidermal
CDK4 up-regulation caused by NF-
 
 
 
B hypofunction, therefore,
requires intact function of both TNFR1 and the JNK cascade.
CDK4 up-regulation in 
 
RelA
 
 
 
/
 
 
 
 epidermis could reflect
either a requirement for CDK4 in the hyperproliferation that oc-
curs with NF-
 
 
 
B impairment or, in light of recent studies (for
review see Su and Stumpff, 2004), it could represent a nones-
sential secondary effect. Distinguishing between these two pos-
sibilities requires the ability to examine the consequences of
NF-
 
 
 
B impairment in the absence of CDK4. Generation of
 
RelA
 
 
 
/
 
 
 
Cdk4
 
 
 
/
 
 
 
 double knockout mice, however, is a formida-
ble challenge because of the death of 
 
RelA
 
 
 
/
 
 
 
 embryos by
E14.5 (Beg et al., 1995) and the decreased viability and infertil-
ity of 
 
Cdk4
 
 
 
/
 
 
 
 mice (Rane et al., 1999). To circumvent this, we
established a conditional approach to inhibit NF-
 
 
 
B by fusing a
4-hydoxytamoxifen (4OHT)-responsive mutant estrogen recep-
tor (ER) domain (Littlewood et al., 1995) to the COOH termi-
nus of 
 
 
 
SP, which is a p50 mutant that dominantly inhibits NF-
 
 
 
B function (Logeat et al., 1991). Expression of 
 
 
 
SP:ER in
epidermal cells selectively blocked NF-
 
 
 
B–directed reporter
gene activity and down-regulated expression of the NF-
 
 
 
B target,
I
 
 
 
B
 
 
 
, in a 4OHT-responsive manner (Fig. 3, a and b). 
 
 
 
SP:ER
thus mediates conditional NF-
 
 
 
B inhibition.
To determine the effects of NF-
 
 
 
B hypofunction in the
setting of CDK4 deficiency in tissue, we first generated multi-
Figure 1. Increased CDK4 levels in RelA
 /  murine epidermis.
(a) Expression of CDK4 protein in RelA
 /  and RelA
 /  skin.
CDK4, CDK2 (orange), the nidogen BMZ marker (green),
and Hoechst 33342 (blue) are shown. Note the increase in
CDK4 protein in RelA
 /  epidermis that extends many cell
layers above the BMZ compared with the lack of altered
CDK2 distribution. The addition of CDK4 peptide immunogen
(peptide) abolished detection, and verified CDK4 antibody
specificity. Control, secondary antibody alone. Bars, 30  m.
(b) CDK4 immunoblots. E14.5 keratinocytes from RelA
 / ,
RelA
 / , and RelA
 /  mice embryos were immunoblotted for
CDK4, RelA, and K14; optical densitometric quantitation for
CDK4 protein is shown below each CDK4 band, normalized
to keratin 14 (K14) loading control.CDK4 REGULATION BY NF- B AND TNFR1/JNK • ZHANG ET AL. 563
ple lines of epidermis-targeted K14- SP:ER transgenic mice;
all three expressing lines demonstrated comparable findings
(unpublished data). K14- SP:ER mice displayed increased
epidermal CDK4 protein levels in response to topical 4OHT
(Fig. 4 a), confirming that NF- B inhibition in mature epider-
mis also produces CDK4 up-regulation. K14- SP:ER mice
were then bred with Cdk4
 /  mice to generate K14- SP:ER
Cdk4
 /  mice. Conditional NF- B blockade via 4OHT in-
creased epidermal proliferation in Cdk4
 /  epidermis, resulting
in marked hyperplasia in 5 d; in contrast, NF- B inhibition in
CDK4-deficient tissue produced no changes in either epider-
mal mitotic index or morphology (Fig. 4, b–d). Therefore,
CDK4 is required for the epidermal hyperproliferation that
occurs with NF- B loss of function.
The present work indicates that suppressing CDK4 up-
regulation and confining CDK4 within the epidermal basal
layer represents a nonredundant role for NF- B RelA that
serves as a physiologic restraint on epidermal growth. More-
over, these findings indicate that CDK4 is essential for the in-
creased epidermal proliferation that accompanies NF- B im-
pairment. This does not reflect a global deficit in proliferation
in CDK4-deficient epidermis, as shown recently by normal hy-
perproliferation of Cdk4
 /  mice in response to other stimuli,
including phorbol ester and wounding (Rodriguez-Puebla et
al., 2002). Although recent neoplasia-focused work suggests
that active NF- B subunits regulate CDK4 expression at the
posttranscriptional level in a proteasome inhibitor–sensitive
manner (Dajee et al., 2003), further studies are needed to deter-
mine the mechanistic basis for CDK4 responsiveness to altered
NF- B function. The current data are consistent with recent
studies directed at epidermal neoplasia, where CDK4 levels
were established to be the critical determinant of whether an
epidermal cell undergoes permanent growth arrest or malignant
transformation (Lazarov et al., 2002; Dajee et al., 2003). This
appears to contradict the orthodox view that regulation of cy-
clin levels is the vital protein expression control mechanism of
cellular proliferation (Murray, 2004) and points to CDK4 pro-
tein as a limiting factor in core cell cycle machinery in normal
and neoplastic epidermis. In agreement with this possibility,
epidermal overexpression of CDK4 causes greater hyperprolif-
eration and malignant transformation than does expression of
cyclin D1 from the same promoter (Robles et al., 1996; Miliani
de Marval et al., 2004). The well-characterized positive regula-
tion of D-type cyclins by NF- B (Guttridge et al., 1999) may
thus be balanced by active suppression of CDK4, indicating
that additional signals, such as JNK induction, are necessary to
overcome CDK4 repression by NF- B to support G1 progres-
sion in epidermis.
We observed that intact TNFR1 and JNK function was
required for CDK4 up-regulation caused by NF- B impair-
ment. While NF- B-JNK antagonism is increasingly recog-
nized as a potent regulator of signaling outcomes in a variety of
settings, this work identifies the first core cell cycle target regu-
lated in an opposing fashion by these pathways. TNFR1 acti-
vates both NF- B as well as JNK (Aggarwal, 2000), and our
Figure 2. CDK4 up-regulation caused by NF- B hypofunction
requires intact function of TNFR1 and JNK. (a) A lack of
CDK4 up-regulation with RelA deficiency in the absence of
TNFR1 in epidermal extract immunoblots from RelA
 / 
Tnfr1
 / ,  RelA
 / Tnfr1
 / , and RelA
 / Tnfr1
 /  mice. (b)
TNF  decreases CDK4 protein levels. Primary human kerati-
nocytes expressing I B  super-repressor mutant (I B M),
active MKK7, or LacZ control were treated with ( ) or with-
out ( ) TNF . (c) NF- B blockade fails to increase TNFR1
expression in keratinocytes that express I B M as well as
MKK7 and LacZ controls. (d) Blockade of I B -induced CDK4
up-regulation by antibodies to TNFR1 in keratinocytes express-
ing I B M or LacZ treated with blocking antibodies to TNFR1
or TNFR2. (e) JNK inhibition prevents CDK4 up-regulation
because of NF- B blockade. Keratinocytes expressing either
LacZ control or I B M were either cotransduced with a retro-
viral expression vector for dominant-negative JNK1-APF (APF)
or treated with the JNK inhibitor SP600125. (f) Northern blot
of human keratinocytes harvested 24 and 48 h after expres-
sion of I B M or LacZ control. (g) Interfering with JNK cas-
cade function blocks CDK4 up-regulation in response to NF- B
blockade in vivo. JNK function was impaired in human epi-
dermis engineered to express I B  via either coexpression of
the dominant-negative JNK-APF mutant or topical application of SP600125. Representative micrographs from five independently generated animals per
group are shown. Note the presence of the CDK4 protein (orange) confined to the basal layer in control tissue (small bracket) and its spread upward in
epidermis expressing I B M (large bracket) compared with the diminished CDK4 distribution seen in I B -expressing epidermis subjected to JNK
inhibition. Bar, 50  m.
Figure 3. Generation of conditional NF- B
loss of function. (a)  SP:ER inducibly inhibits
NF- B reporter gene expression in response
to 4OHT. Reporter gene activity   SD from
triplicate independent experiments is shown
in cells transfected with luciferase reporter
plasmids for NF- B as well as EF-1  specific-
ity control after 48 h with or without 4OHT
(50 nM). (b) Inducible suppression of an
endogenous NF- B target. Extracts from
primary  human keratinocytes transduced
with retrovectors encoding either LacZ or
 SP:ER and grown for 48 h in the absence
( ) or in the presence ( ) of 4OHT were
immunoblotted with I B  antibodies.JCB • VOLUME 168 • NUMBER 4 • 2005 564
findings suggest that CDK4 levels, and their resultant effects
on epidermal growth control, may depend on the relative bal-
ance between these two competing pathways. Although pro-
growth functions by the JNK cascade, aside from CDK4 effects
noted here, have not been systematically assessed in normal
epidermis, the data suggest that JNK and its AP1 targets facili-
tate epidermal neoplasia. Inhibition of JNK–AP1 function, via
deletion of either Jnk2 (Chen et al., 2001) or c-Jun (Zenz et al.,
2003) as well as by overexpression of dominant-negative c-Jun
(Thompson et al., 2002) increases resistance to topical chemi-
cal carcinogenesis, but oncogenic AP1 subunits promote epi-
dermal tumor formation (Wang et al., 1995). Although further
studies are needed to define the role of JNK cascade action in
epidermal growth control, these data are consistent with a po-
tential role for this NF- B-opposed pathway in promoting epi-
dermal proliferation.
Our findings suggest that the CDK4-dependent epidermal
growth deregulation that occurs with NF- B inhibition is intrinsic
to epidermal cells and does not require significant inflammation.
Pure cultures of both murine and human keratinocytes with
impaired NF- B function caused by RelA deficiency and I B 
overexpression, respectively, display both CDK4 up-regulation
and hyperproliferation, underscoring the cell-autonomous nature
of this process. In tissue, we detected neither an influx of in-
flammatory cells nor an up-regulation of inflammatory cyto-
kines associated with the CDK4 induction that occurs with
conditional NF- B blockade (Fig. 4 b and not depicted). This
lack of inflammation is consistent with prior findings with con-
stitutively RelA-deficient epidermis (Zhang et al., 2004). Al-
though inflammatory cell infiltration is readily excluded in
these experiments by immunohistochemical analysis, such
analyses do not exclude action by basal levels of local proin-
flammatory cytokines, such as TNF , which are constitutively
expressed by epidermal cells. TNF  represents a likely ligand
for TNFR1 in the epidermal growth deregulation caused by
NF- B loss of function, as demonstrated recently by RelA
 / c-
Rel
 /  Tnf 
 /  mice, which display epidermal hypoplasia (Gu-
gasyan et al., 2004). Moreover, the blockade of CDK4 up-regu-
lation by antibodies to TNFR1 in pure cultures of keratinocytes
observed here suggests that TNFR1 operates in an epithelial
cell-intrinsic manner rather than by a more indirect route, such
as via inflammatory cells. This premise is supported by the re-
cent demonstration that Tnfr1 deletion abolishes hyperplasia
and tumorigenesis in epidermis overexpressing I B  in a man-
ner that cannot be restored by administration of Tnfr1 wild-
type hematopoietic cells (Lind et al., 2004). However, Lind et
al. (2004) demonstrated that significant CDK4 up-regulation
was observed only in tumorigenesis, and further study of dif-
ferences between the K5-I B  mice and the three distinct ap-
proaches pursued here is merited. Together, these data support
a working model in which locally produced TNF  activates
epidermal cell TNFR1, which then alters CDK4 protein levels
in a NF- B and JNK-regulated manner to control cell cycle
progression in epidermis.
Materials and methods
Cell culture and gene transfer
Primary human keratinocytes were grown as described previously (Rob-
bins et al., 2001). We grew murine keratinocytes from RelA
 / , RelA
 / ,
and RelA
 /  E14.5-old embryos for 3 d before performing protein extrac-
tion. For gene transfer, 4   10
4 keratinocytes were plated on 35-mm wells
1 d before infection with retroviruses. No drug selection was used at any
point, and  99% efficiency gene transfer was verified by immunofluores-
cence staining (Robbins et al., 2001). Retroviruses were generated encod-
ing LacZ, I B M (Seitz et al., 1998), and dominant-negative JNK1-APF
(Derijard et al., 1994) in the pLZRS backbone. Keratinocytes infected with
retroviruses encoding LacZ, I B M, or MKK7 were treated with either neu-
tralizing antibodies against TNFR1 (50  g/ml; mAb 225; R&D Systems),
TNFR2 control (50  g/ml; mAb 226; R&D Systems), the JNK inhibitor
SP600125 (10  M; BIOMOL Research Laboratories, Inc.), or TNF  (15
ng/ml; Sigma-Aldrich) for 48 h before immunoblotting.
Figure 4. Epidermal hyperproliferation caused by NF- B hypofunction
requires CDK4. (a) Epidermal CDK4 protein levels increase upon inducible
inhibition of NF- B function. Epidermal extracts from wild-type (WT) and
K14- SP:ER transgenic mice (TG) treated with 4OHT or vehicle control for
5 d were immunoblotted for  SP:ER, CDK4, and actin. (b) Epidermal
hyperplasia occurs with inducible NF- B blockade and is CDK4 depen-
dent.  Histology of K14- SP:ER/CDK4
 /  and K14- SP:ER/CDK4
 / 
murine skin treated with either 4OHT or vehicle alone for 1 wk. Note
4OHT-induced hyperplasia in K14- SP:ERCDK4
 /  epidermis and its
complete absence in K14- SP:ERCDK4
 /   skin. Representative micro-
graphs are shown for five independent mice per group. Bars, 50  m.
Asterisks denote normal hair follicles, and brackets delineate thickness of
intrafollicular epidermis. (c) CDK4 is required for the increased prolifera-
tion seen with NF- B inhibition. Note the increase in green Ki-67( ) cells
(arrows) that occurs with NF- B blockade only in the presence of CDK4.
Bar, 50  m. Ki-67 (green) and nidogen BMZ marker (orange) are shown.
(d) Mitotic index quantitation of Ki-67( ) epidermal cells/100  m skin of
K14- SP:ER/CDK4
 /  and K14- SP:ER/CDK4
 /  murine skin in response
to 4OHT. Error bars represent means   SD from five independent mice for
each group.CDK4 REGULATION BY NF- B AND TNFR1/JNK • ZHANG ET AL. 565
Animal studies
RelA
 / , RelA
 / , and RelA
 /  skin tissues were generated through em-
bryonic skin grafting on immunodeficient CB.17 scid/scid mice (Oro et
al., 1997) and analyzed at 6 wk. Inducible NF- B blockade was
achieved through in-frame COOH-terminal fusion of the p50 mutant ( SP)
dominant negative for NF- B function (provided by A. Israel, CNRS URA
2582, Paris, France; Logeat et al., 1991) with the 4OHT-responsive mu-
tant ER (Littlewood et al., 1995).  SP:ER fusion was subcloned into the
pENTR1A plasmid (Invitrogen) and transferred to pLZRS retrovector and
pBSKII keratin 14 promoter plasmids modified to contain GATEWAY des-
tination sequences (GIBCO BRL). We confirmed expression of  SP:ER pro-
tein in three independent lines of K14- SP:ER transgenic mice by immuno-
blotting epidermal extracts. K14- SP:ER mice were crossbred with Cdk4
 / 
mice (provided by E. Reddy and M. Barbacid, Temple University School
of Medicine, Philadelphia, PA; Rane et al., 1999) to generate K14 SP:
ER,Cdk4
 /  mice. To induce NF- B blockade, we applied 1 mg/d 4OHT
(in 95% ethanol) for 5 d on back skin of 4-wk-old mice; five mice/group.
For human skin studies, primary human keratinocytes were engineered to
express LacZ control, I B , or I B    dominant-negative JNK1 (JNK-APF)
and grafted on immunodeficient CB.17 scid/scid mice (n   5 indepen-
dent grafts per analyzed group). For JNK inhibition, we applied 1 mg/d
SP600125 topically to human skin grafts for 5 d before analysis.
Protein expression analysis and microscopy
For immunostaining, 5- m cryosections were incubated either with primary
rabbit antibodies against CDK4 or CDK2 (Santa Cruz Biotechnology, Inc.)
along with rat anti–mouse nidogen (CHEMICON), or rat anti–Ki-67 (Dako-
Cytomation) along with rabbit anti–mouse laminin 5 (gift of M.P. Marinko-
vich, Stanford University, Stanford, CA) followed by Cy2 or Cy3-conjugated
secondary antibodies (Jackson ImmunoResearch Laboratories). Regener-
ated human skin cryosections were incubated with primary mouse antibod-
ies against CDK4 (LabVision) along with rabbit anti–collagen VII (Calbio-
chem) followed by Cy2 or Cy3-conjugated secondary antibodies. Tissue
sections were counterstained with Hoechst 33342 DNA for 15 s to visualize
nuclei. Images were captured on a Zeiss Axiovert 100M.
Reporter gene assays
For reporter gene assays, cells were transfected with plasmids encoding
 SP:ER and either NF- B or EF1  luciferase reporter plasmids along with
CMV-driven renilla-luciferase internal controls for transfection efficiency us-
ing FuGENE reagents (Roche). 8 h after transfection, cells were treated
with ethanol solvent or 50 nM 4OHT for 48 h before analysis with dual lu-
ciferase reagents (Promega).
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